Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma

Trial Profile

Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Glioblastoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 10 May 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
    • 27 Apr 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
    • 01 May 2015 Status changed from not yet recruiting to recruiting as per M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top